Pulike Biological Engineering (603566.SS) Stock Price

Pulike Biological Engineering Price

SSE·CLOSED
10.29
​
Market closed

Revenue has compounded at 9.2% per year over the past 16 years to 1.09 B CNY. Earnings per share have grown at 4.4% per year over the last 16 years. Pulike Biological Engineering's net margin stands at 17.0%, down from 22.2% several years earlier. Pulike Biological Engineering currently offers a dividend yield of about 5.83%. The payout ratio is around 111% of earnings. The dividend has grown at 16.7% per year over the past 9 years. Analysts set a median price target of 17.25 CNY, implying 67.6% above the current price. Of 6 analysts, 5 rate the stock a buy — an overall Buy consensus.

Pulike Biological Engineering stock price

Access this data via the Eulerpool API

Pulike Biological Engineering business model & stock analysis

Pulike Biological Engineering, Inc. engages in the research, development, manufacturing and sale of biological products for animals, chemical drugs and Chinese veterinary drugs. The company is headquartered in Luoyang, Henan and currently employs 1,718 full-time employees. The company went IPO on 2015-05-18. Inc is principally engaged in the research, development, production and distribution of veterinary biological products and chemical medicines. The firm's veterinary biological products include vaccine and antibody, applied in the prevention and controlling of infection to epidemic disease for poultry and livestock. Its veterinary chemical medicines are mainly used in the treatment of epidemic diseases of poultry and livestock.

Frequently asked questions about Pulike Biological Engineering

Analysts currently set an average price target of 17.25 CNY for the Pulike Biological Engineering stock (median: 17.25 CNY), implying +67.6 % versus the latest price. The consensus is based on 6 analyst ratings.

6 analysts currently rate the Pulike Biological Engineering stock: 5 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Pulike Biological Engineering to generate revenue of 1.03 B CNY and earnings per share of 0.47 CNY.

Converted at the current exchange rate, the Pulike Biological Engineering share trades at 1.37 EUR (10.29 CNY).

The Pulike Biological Engineering share (603566.SS) is listed on 1 stock exchanges, including: Shanghai (603566.SS).

The expected revenue of Pulike Biological Engineering is 1.03 B CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Pulike Biological Engineering is 161.55 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Pulike Biological Engineering is currently 21.74. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pulike Biological Engineering stock.

The price-to-sales ratio (P/S) of Pulike Biological Engineering is currently 3.42. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pulike Biological Engineering stock.

The Eulerpool Quality Score for Pulike Biological Engineering is 4/10.

The ISIN of Pulike Biological Engineering is CNE1000025N0. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Pulike Biological Engineering is 603566.SS. The ticker symbol is used to trade Pulike Biological Engineering shares on the stock exchange.

Fair ValueTerminal
9.78 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
634,387.66 CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
CNY
Initial public offering
May 18, 2015
ISIN
CNE1000025N0
Cusip
Y7166U101
Market capitalization
3.54 B CNYMid Cap
52-Week Range
PEG
1.51
P/E ratio
P/Ee 2026
21.89
P/Ee 2027
20.18
P/Ee 2028
15.36
P/S
P/Se
3.42
EV/EBIT
17.98
P/B Ratio
1.36
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
7.05 %
Dividend
Dividend yield
5.83 %
Est. Dividend Yield
7.77 %
Payout Ratio
110.72 %
Dividend growth Ø5Y
24.57 %
Dividend payments per year
2
Dividend paid since
10 years
Dividend not reduced since
1 year
Dividend increased since
1 year
Dividend withholding tax
10.00 %
Last updated Oct 11, 2026, 3:09 PM

Pulike Biological Engineering Peer Group

Pulike Biological Engineering Ticker

SHH · 603566.SS

Pulike Biological Engineering FIGI

603566:CH · BBG002WTM458603566:CG · BBG002WTM467603566:C1 · BBG01FRBCS33